Effects of the combination of TRC105 and bevacizumab on endothelial cell biology. - Test2 - elhamkhani - TriplyDB

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

http://www.wikidata.org/entity/Q41889215

about

Anti-angiogenic alternatives to VEGF blockade Endoglin promotes angiogenesis in cell- and animal-based models of retinal neovascularization.Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib Cancer prevention and therapy through the modulation of the tumor microenvironment.Dichotomous roles of TGF-β in human cancer.The role of endoglin in post-ischemic revascularization.Endoglin-based biological therapy in the treatment of angiogenesis-dependent pathologies.Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer.Endoglin and alk1 as therapeutic targets for hereditary hemorrhagic telangiectasia.CD105 Over-expression Is Associated with Higher WHO Grades for Gliomas.Endoglin (CD 105) as a potential prognostic factor in neuroblastoma.Effect of the monoclonal antibody TRC105 in combination with Sunitinib on renal tumor derived endothelial cells.Soluble endoglin regulates expression of angiogenesis-related proteins and induction of arteriovenous malformations in a mouse model of hereditary hemorrhagic telangiectasia

P2860

Q26775947-FE25D47A-AC87-4FF0-B0F8-62A97E72E21E Q34341837-C9542321-9ECB-4CF2-A072-59F1913DD65C Q35961353-BA0A1266-897C-4C22-B2F7-868553D8AE22 Q36223538-0D1AE8B0-A568-46F7-8256-512CEDF3A555 Q37058267-DC486996-6258-48EB-A1F1-208C18B683D1 Q39027205-53270622-732E-447E-8BBA-335C6B92220A Q39036151-780D2355-2F23-4D00-B43C-9C90BE5FACD9 Q39401943-363ABF72-40CF-4872-BC3E-620A43766843 Q40068276-2C51C9F1-864B-4E30-8745-7E9C78BE4A39 Q47968783-8AE15309-6E5A-4346-93FC-18A5F6607168 Q48900892-6F28FCA2-0CA6-4483-9FF5-21C814D4DD5F Q53616024-8FC2C31F-2406-4991-97ED-3ED05D8F094A Q54977476-E86BB18F-0873-425D-BBC8-C731BB6D8E53 Q58703191-C3DBFA3F-E4D2-4358-8A46-2DCCB2049AFB

P2860

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

http://www.wikidata.org/entity/Q41889215

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

@en

type

label

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

@en

prefLabel

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

@en

P1433

Q41889215-4D44B55A-BE10-4CBE-B523-0C147E96B000

P1476

Q41889215-A858C122-D21A-42FF-B2CA-6A8DEACC87F2

P2093

Q41889215-20737A6A-4362-4547-BA01-6FF6A4BC1D78

Q41889215-A8D1F3D3-B243-413B-B46D-68071E64FBD3

Q41889215-D370AF43-E604-4A72-8BB0-2D74D63FCEF9

Q41889215-D5C05F5F-AE59-4FA4-97BB-D5E0AF034638

Q41889215-E235C1D3-FD3B-43DB-815E-49A729482E0D

Q41889215-F49058D7-A6A4-4035-A1B6-14F6B227C3C2

P2860

Q41889215-02585238-26F3-4715-9EB1-A6E0ACE2E987

Q41889215-0B5A34BF-1C33-4150-8B7E-6ABA2FA4F6A2

Q41889215-0CA1AC84-CDDF-47DD-8388-317A5F966FDD

Q41889215-1AC39394-9311-456D-BA41-F34A96C74AFD

Q41889215-1CE78583-3AD0-4AB1-A04A-280E728A689D

Q41889215-1F317698-FA00-4B85-AAD0-B39EC3A6CDCC

Q41889215-2DB6108B-04BC-4370-A5D4-5ACAC367506C

Q41889215-337411EA-88FA-426E-9019-8D886D5C740F

Q41889215-3ACD1520-CB3D-480D-A66F-4B665EB71AAE

Q41889215-45AD302A-448F-416B-B66B-D6D9D6B88B9C

P2888

Q41889215-C4937DDA-1103-491D-AC1F-BA48C0983AFE

P304

Q41889215-8C50252D-0E46-4320-881B-77F679E4BDA8

P31

Q41889215-9F185AE4-1122-43B6-B7C3-2D8BCFFF29C4

P356

Q41889215-80AEBFCA-53C3-46FB-A6F9-56D01CABF636

P433

Q41889215-06BED379-3449-4796-829E-79C0EA577A34

P478

Q41889215-21DBD9BB-6CBA-4FBF-9E6B-2D30D356D109

P577

Q41889215-26A97E3D-130A-41E2-9AD2-30531951E884

P5875

Q41889215-73A28486-4ACD-4C90-8B30-9D3A8B7A0699

P6179

Q41889215-6DD9602A-25A0-49CA-9E38-3A31D096CDB2

P698

Q41889215-BB53A35D-9003-4A6B-87F2-909224D62472

P921

Q41889215-7858330D-658B-439E-8260-5523149639E4

Q41889215-D32999D6-4569-4890-872F-49D8C7DEB98F

P932

Q41889215-FF67D814-8D65-445F-8C61-C7CBAEF4E7F1

P356

S10637-014-0129-Y

P1433

Investigational New Drugs

P1476

Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.

@en

P2093

Andrew B Nixon

http://www.w3.org/2001/XMLSchema#string

Charles P Theuer

http://www.w3.org/2001/XMLSchema#string

Gerard C Blobe

http://www.w3.org/2001/XMLSchema#string

Herbert I Hurwitz

http://www.w3.org/2001/XMLSchema#string

Hongyu Tian

http://www.w3.org/2001/XMLSchema#string

Yingmiao Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex

Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling

Endoglin is a component of the transforming growth factor-beta receptor system in human endothelial cells

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Angiogenesis in cancer and other diseases

Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the Lim family of proteins

BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis

Angiogenesis: an organizing principle for drug discovery?

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

P2888

s10637-014-0129-y

P304

851-859

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-014-0129-Y

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P577

2014-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263708137

http://www.w3.org/2001/XMLSchema#string

P6179

1022227595

http://www.w3.org/2001/XMLSchema#string

P698

24994097

http://www.w3.org/2001/XMLSchema#string

P921

P932

4169868

http://www.w3.org/2001/XMLSchema#string